Detail page

Knowledge Web

Person

Elias K. Mai (1985-)

Arzt

Name	Elias K. Mai
Time	1985- (Date of birth and death)
Place	Heidelberg (Wirkungsort) Darmstadt (Geburtsort) Deutschland
Gender	männlich
Academic degree	PD (an der Medizinischen Fakultät der Universität Heidelberg) (2021) Dr. med. (an der Medizinischen Fakultät der Universität Heidelberg) (2014)
Profession	Arzt (characteristic profession)
Variant	Elias Karl Loos (Geburtsname) (früherer Name) Elias Karl Mai E. K. Mai
Related	Medizinische Klinik und Poliklinik (Heidelberg, 5)
Further information	Mitarbeiter der Sektion Multiples Myelom der Inneren Medizin V
Record type	Person
GND-Identifier	1049182545
Record ID	1049182545
Involved in show all Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma A systematic classification of death causes in multiple myeloma Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology Functional consequences of Tie1-silencing in endothelial cells

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Elias K. Mai (1985-)

Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significance

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study

The impact of divergent forms of social support on health-related quality of life in patients with multiple myeloma and its precursor states

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients

Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial

Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

A systematic classification of death causes in multiple myeloma

Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology

Functional consequences of Tie1-silencing in endothelial cells